This undiscovered CBD play is on the verge of disrupting the industry
With recent health Canada approval they are poised to explode
Read more here

STX Insider Trading (Shield Therapeutics plc (STX.L))

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £130,000
Insider Selling (Last 12 Months): GBX 0

Shield Therapeutics plc (STX.L) Insider Trading History Chart

Shield Therapeutics plc (STX.L) Share Price & Price History

GBX 54.50
▲ +3 (5.83%)
As of 02/25/2021 01:54 PM ET
Days: 30 | 90 | 365
This undiscovered CBD play is on the verge of disrupting the industry
With recent health Canada approval they are poised to explode
Read more here

Shield Therapeutics plc (STX.L) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2021Tim WattsInsiderBuy100,000GBX 60£60,000
12/11/2020Tim WattsInsiderBuy100,000GBX 70£70,000
4/25/2019Mark SampsonInsiderBuy22,042GBX 91£20,058.22
4/16/2019James M KarisInsiderBuy4,000GBX 81£3,240
9/21/2018Carl SterrittInsiderBuy88,235GBX 34£29,999.90
See Full Table
Shield Therapeutics plc (STX.L) logo
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More

Today's Range

Now: GBX 54.50
51
54.50

50 Day Range

MA: GBX 54.45
48.50
62.80

52 Week Range

Now: GBX 54.50
39.10
153

Volume

149,242 shs

Average Volume

1,058,462 shs

Market Capitalization

£64.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Shield Therapeutics plc (STX.L)?

Shield Therapeutics plc (STX.L)'s top insider shareholders include:
  1. James M Karis (Insider)
  2. Mark Sampson (Insider)
  3. Tim Watts (Insider)
Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!